@article {Nishimura159, author = {S. Nishimura and H. Tsuda and Y. Hashiguchi and K. Kokawa and R. Nishimura and O. Ishiko and S. Kamiura and K. Hasegawa and N. Umesaki}, title = {Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis}, volume = {17}, number = {1}, pages = {159--163}, year = {2007}, doi = {10.1111/j.1525-1438.2006.00728.x}, publisher = {BMJ Specialist Journals}, abstract = {The aim of this study was to evaluate the efficacy and toxicity of irinotecan and doxorubicin in the treatment of patients with early recurrent or platinum-refractory ovarian cancer. Nineteen woman from five different institutions were treated. Two patients had platinum-refractory cancer, 11 had platinum-resistant disease, and 6 had platinum-sensitive tumors. An intravenous infusion of Irinotecan (50mg/m2) was given on days 1, 8, and 15, while doxorubicin (40mg/m2) was administered as an intravenous bolus on day 3. This treatment schedule was repeated every 4 weeks. Among the 13 patients defined as having platinum-refractory/platinum-resistant disease, 4 patients achieved a clinical response (30.8\%, 95\% CI: 9.1{\textendash}61.4), while only one of 6 patients defined as having platinum-sensitive disease achieved a clinical response (16.7\%, 95\% CI: 0.4{\textendash}64.1). Leukopenia and neutropenia were the major dose- limiting toxicities. Grade 3 or 4 leukopenia and neutropenia were noted in 24 (48\%) and 33 (66\%) of the courses, while febrile neutropenia occurred in 2 courses. Five patients (26\%) had grade 2 or worse diarrhea during 7 courses. Our data demonstrated that this regimen might be comparable to standard approved agents in patients with early recurrent or platinum refractory ovarian cancer.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/17/1/159}, eprint = {https://ijgc.bmj.com/content/17/1/159.full.pdf}, journal = {International Journal of Gynecologic Cancer} }